Lowering blood glucose levels in people with type 2 diabetes has clear benefits for preventing microvascular complications and potential benefits for reducing macrovascular complications and death.
Treatment needs to be individualised for the person with diabetes. This should start with selection of the appropriate glucose and glycated haemoglobin targets, taking into account life expectancy, and the wishes of the person with diabetes. For most people, early use of glucose lowering therapies is warranted. A range of recently available therapies have added to our range of options for lowering glucose but this has made the clinical pathway for treating diabetes more complicated.
Disclaimer: The information contained in this website is for general information only. It is designed to be educational and is not intended to be and is not a complete or definitive statement on any area of medical practice or procedure. The Society, its directors and other officers make no express or implied warranties, as to suitability for a particular purpose or otherwise, with respect to any information included on this website. Rapid advances in medicine may cause information contained in this website to become outdated or subject to debate. Visitors to this website who are not medical practitioners qualified in the field should seek further professional advice before any action is taken in relation to the matters described or referred to on this website.
The blood glucose management algorithm for type 2 diabetes outlines the risks, benefits and costs of available therapies and provides an approach for how to incorporate older and newer agents.
Treatment needs to be individualised for the person with diabetes. A selection of case studies have been created to help guide the management process.